Resource Download
FDA’s New Breakthrough Therapy Designation: What does it mean for Pricing

The full impact of the breakthrough therapy designation remains to be seen,but the financial stakes are high. Therefore, it is important to assess how P&MA planning practices need to be adapted to take advantage of a potential breakthrough designation. Re-evaluation of P&MA activities is prudent for any manufacturer hoping to secure big wins in the face of future break-through drug launches.

 

Download your copy

©2022 EPP – Pricing and RGM Platform

Continue the conversation on: LinkedIn - Youtube